{"id":4596,"date":"2020-05-06T17:15:59","date_gmt":"2020-05-06T15:15:59","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=4596"},"modified":"2020-10-07T19:13:07","modified_gmt":"2020-10-07T17:13:07","slug":"axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/","title":{"rendered":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-full wp-image-3817\" src=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\" alt=\"\" width=\"138\" height=\"86\" \/><\/p>\n<p>May 5, 2020&#8211;\u00a0Axonics Modulation Technologies, Inc.\u00a0(NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (\u201cSNM\u201d) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives.<\/p>\n<p><b>Recent Business &amp; Financial Highlights<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>Net revenue was\u00a0$26.3 million\u00a0in the first quarter of 2020, the first full quarter of commercial results following\u00a0U.S. Food &amp; Drug Administration\u00a0(\u201cFDA\u201d) approval of the Axonics r-SNM<sup>\u00ae<\/sup>\u00a0System in\u00a0November 2019. Sales momentum accelerated throughout the first quarter, peaking in mid-March prior to COVID-19 related postponement of elective procedures.<\/li>\n<li>Over 350 unique accounts (hospitals and ambulatory surgery centers) in\u00a0the United States\u00a0implanted patients with the Axonics r-SNM System in the first quarter of 2020.<\/li>\n<li>Over 110 facility agreements with national and regional IDNs as well as large urology groups and ambulatory surgery centers have been signed since the\u00a0U.S.\u00a0launch. Included in this group are agreements with three of the largest national IDNs in the\u00a0U.S.\u00a0which were executed in March. Another 85 agreements are currently in process.<\/li>\n<li>In\u00a0January 2020, the FDA approved an enhanced, second-generation programmer for the Axonics r-SNM System under a premarket approval (\u201cPMA\u201d) supplement. The new programmer features, among other things, a predictive programming algorithm that translates intra-operative responses and suggests how to program the patient for optimum therapy, thereby reducing the need to adjust post-implant therapy.<\/li>\n<li>In\u00a0April 2020, Axonics submitted a PMA supplement to the FDA for the purpose of gaining full-body MRI conditional labeling for 3.0T MRI scans. Both 1.5T and 3.0T labeling is approved in\u00a0Europe\u00a0under the CE Mark. In\u00a0September 2019, the FDA approved full-body labeling for 1.5T MR scanners. Axonics has since performed all the required tests to support the rationale for full-body 3.0T labeling.<\/li>\n<li>In\u00a0April 2020, the FDA approved a next generation rechargeable implantable neurostimulator (\u201cINS\u201d) for the Axonics r-SNM System under a PMA supplement. The new INS decreases how frequently a patient needs to recharge their implanted device to once a month for about one hour and for some patients, once every other month. The next generation Axonics INS is expected to begin shipping to\u00a0U.S.\u00a0customers early in the third quarter of 2020.<\/li>\n<\/ul>\n<p>Raymond W. Cohen, CEO of Axonics, commented, \u201cWe are quite proud of this quarter\u2019s exceptional revenue result considering we had only been in the market for two months prior to the start of 2020. <em><strong>Moreover, we believe that this result ranks among the highest revenue total generated in the history of the medical device industry for a company\u2019s first full quarter of sales in the\u00a0U.S.\u00a0following FDA approval<\/strong><\/em>. The results are a testament to the quality of our 170 person\u00a0U.S.\u00a0commercial team and were driven by the overwhelmingly positive response from the SNM implanting community and their patients to the introduction of a bespoke SNM device that is intuitive, fuss-free, long-lived, MRI compatible, safe and clinically effective. This quarter\u2019s results reinforce our confidence that the SNM market is poised for meaningful expansion in the years ahead, driven to a large extent by Axonics\u2019 continuous innovation and commitment to increasing patient awareness. As elective procedures are rescheduled, we expect to be very active in the months ahead as more patients say \u2018yes\u2019 to Axonics and SNM therapy. Despite the setback from COVID-19, we remain bullish about our prospects for continued growth in 2020 and beyond.\u201d<\/p>\n<p>Mr. Cohen\u00a0continued, \u201cThe Axonics team would like to express its gratitude to the courageous and selfless healthcare workers providing care for those impacted by COVID-19. At Axonics, we remain focused on supporting our customers and their patients as well as protecting the health of our employees and their families.\u201d<\/p>\n<p><b>First Quarter 2020 Financial Results<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>Net revenue was\u00a0$26.3 million\u00a0in the first quarter 2020, as compared to net revenue of\u00a0$1.1 million\u00a0for the same period of the prior year.<\/li>\n<li>Net revenue from\u00a0the United States\u00a0accounted for\u00a0$25.0 million, with select European markets and\u00a0Canada\u00a0accounting for the balance of first quarter 2020 revenue.<\/li>\n<li>Gross margin was 62.4% in the first quarter 2020, as compared to 49.2% for the same period of the prior year.<\/li>\n<li>Operating expenses were\u00a0$31.1 million\u00a0in the first quarter 2020, as compared to\u00a0$14.1 million\u00a0for the same period of the prior year. This increase was primarily due to higher personnel costs for the\u00a0U.S.\u00a0commercial team and in other parts of the organization.<\/li>\n<li>Net loss was\u00a0$14.6 million\u00a0in the first quarter 2020, as compared to\u00a0$13.1 million\u00a0for the same period of the prior year.<\/li>\n<li>As of\u00a0March 31, 2020, cash, cash equivalents and short-term investments were\u00a0$159.8 million, as compared to\u00a0$183.7 million\u00a0at\u00a0December 31, 2019.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>May 5, 2020&#8211;\u00a0Axonics Modulation Technologies, Inc.\u00a0(NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (\u201cSNM\u201d) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives. Recent Business &amp; Financial Highlights Net revenue was\u00a0$26.3&#8230;<\/p>\n","protected":false},"author":2,"featured_media":3817,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-4596","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"May 5, 2020&#8211;\u00a0Axonics Modulation Technologies, Inc.\u00a0(NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (\u201cSNM\u201d) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives. Recent Business &amp; Financial Highlights Net revenue was\u00a0$26.3...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-06T15:15:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-10-07T17:13:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\" \/>\n\t<meta property=\"og:image:width\" content=\"138\" \/>\n\t<meta property=\"og:image:height\" content=\"86\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives\",\"datePublished\":\"2020-05-06T15:15:59+00:00\",\"dateModified\":\"2020-10-07T17:13:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\"},\"wordCount\":779,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\",\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\",\"name\":\"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\",\"datePublished\":\"2020-05-06T15:15:59+00:00\",\"dateModified\":\"2020-10-07T17:13:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png\",\"width\":138,\"height\":86},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/","og_locale":"en_US","og_type":"article","og_title":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS","og_description":"May 5, 2020&#8211;\u00a0Axonics Modulation Technologies, Inc.\u00a0(NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable Sacral Neuromodulation (\u201cSNM\u201d) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the first quarter 2020 and provided an update on operational initiatives. Recent Business &amp; Financial Highlights Net revenue was\u00a0$26.3...","og_url":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2020-05-06T15:15:59+00:00","article_modified_time":"2020-10-07T17:13:07+00:00","og_image":[{"width":138,"height":86,"url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png","type":"image\/png"}],"author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives","datePublished":"2020-05-06T15:15:59+00:00","dateModified":"2020-10-07T17:13:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/"},"wordCount":779,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png","articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/","url":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/","name":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage"},"thumbnailUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png","datePublished":"2020-05-06T15:15:59+00:00","dateModified":"2020-10-07T17:13:07+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#primaryimage","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2018\/02\/Axonics.png","width":138,"height":86},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/fr\/axonics-modulation-technologies-reports-financial-results-for-the-1st-quarter-2020-and-provided-an-update-on-operational-initiatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"\u00a0Axonics Modulation Technologies reports financial results for the 1st quarter 2020 and provides an update on operational initiatives"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/4596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=4596"}],"version-history":[{"count":0,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/4596\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media\/3817"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=4596"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=4596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}